Rohan Patel

Exactly, it's that feeling when you're staring at all those model options, and you just want the one that actually works without having to spend hours testing it. You've got 600 types of sprinkles, but half of them are just variations of the same vanilla, and you're still stuck in the checkout line trying to decide if the new one will crash your whole project or not. It's enough to make you just pick the default and be done with it.

It's exactly that kind of real-world cost that makes the whole "things just get cheaper" narrative so frustrating. The genome sequencing project tracking those actual costs over twenty-one years really lays bare that it's not some abstract magic; someone is still footing the bill for all those cheaper chips, and the next step is to ask who pays for the next round of those machines.

That's true that the cost of sequencing plunged, but that was just the sequencing process itself. There's a whole story of data interpretation after that, a huge cost to figure out what all those letters actually mean for a person's health; a bit like getting a house inspection where you still need a builder to tell you what to fix. It's never just the raw data; the real work, and the real expense, is understanding the human story it tells.

To say Gordon Moore's initial observation about microchips directly informed genome sequencing costs feels like skipping the whole story of discovery between them.
It’s like saying the first bicycle informed rocket science; both move, yes, but the journey to space involved entirely different breakthroughs and minds.
Sure, faster computers eventually helped, but the real change in sequencing costs came from incredible advancements in biology and chemistry, like those new ways to amplify DNA.
Without those specific innovations, a faster general-purpose chip wouldn't have cut the price of mapping a human genome.

When Gordon Moore first wrote about chips getting smaller, it offered a story for rapid progress, a kind of template for the future, but let's not pretend a paper alone drove down the actual cost of sequencing a genome.
It's like someone telling you a recipe for paella; it's a good guide, but you still need to find the saffron, the rice, and most importantly, the skill in the kitchen to make it happen.
The National Human Genome Research Institute’s tracking of those costs shows the real action was in labs, with scientists inventing new chemicals and building machines, not just reading about transistor density.
The original article set a narrative beat for progress, but the journey itself was paved with hard-won biological breakthroughs and massive practical investment, not just an idea.
For instance, the development of technologies like next-generation sequencing, with its entirely new approach to reading DNA, required immense scientific effort and funding, far beyond what any single informational benchmark could provide.

Gordon Moore's paper from '65 was a good story of observation, a pattern he saw in microchips, but it wasn't the engine driving the cost drops for sequencing a human genome decades later.
That's like saying my grandmother's recipe for paella is why a modern chef can create molecular gastronomy; one offers a benchmark, the other builds something new, ingredient by ingredient, and with entirely different tools and challenges.
The National Human Genome Research Institute might have used it for comparison, sure, to show how well they were doing, but the scientists in their labs made the real progress.
If their research grants dried up, no amount of referencing Moore's Law would keep the sequencing costs falling year after year; the human effort and funding are the true plot points here.

This talk of Moore's Law being the fundamental reference for mapping a human genome always misses the actual story of what happened in the labs.
My neighbor, Carmen, needed a specific genetic test, and the doctors spoke about new lab techniques and faster machines, not some article about silicon chips from decades ago.
The practical, hands-on improvements in chemistry and equipment were what brought down the price for her, not an abstract principle.
If the specialized reagents ran out or the technicians weren't properly trained, Moore's Law wouldn't have helped Carmen one bit.

To say Moore's Law is the foundational context for genome sequencing cost drops feels like quite a stretch, doesn't it?
It's a lovely thought, sure, but in my experience, the actual story of progress is always far more granular, made of dedicated people and their practical struggles.
When my neighbour's child needed genetic screening last year, the hospital talked about specific advances in their lab techniques and the new equipment, not some abstract law from a tech magazine.
The real beats of that journey are in the quiet work of scientists, perfecting their methods, not in a general observation about chip density.

Gordon Moore's article might have started a conversation, but it wasn't the only beat in the story of how genome sequencing costs came down. I remember when my niece was trying to get funding for her genetics lab years ago; they were always talking about new equipment, not just some old article.
To frame it as if one paper gave all the context for two decades of research is to miss the arc of genuine scientific effort.
It's like saying a recipe for paella from the 70s is the only reason every chef today knows how to cook; there are so many turns in the road, new ingredients, and different hands involved.
The real stakes were always in the daily work, the grants, and the bright minds pushing limits, not just one early observation.

This idea of Moore's Law being a "baseline benchmark" for tracking genome sequencing costs just feels too definitive, almost like an old family legend that everyone keeps repeating but doesn't quite hold up anymore. It reminds me of Manolo, my neighbor, who always insists the price of olive oil sets a "baseline" for everything, but then the harvests change, new pests arrive, and his old baseline is suddenly useless.
What truly matters are the scientists in the lab, the unexpected breakthroughs, the clever new materials they invent—those are the real forces pushing things forward, not some article from decades past.
It’s a nice story, but it doesn't show the true, messy, human arc of progress in the lab, where real people faced new turns and discovered things nobody predicted.
Comparing it to an old paper from the 60s is like saying the speed of a horse-drawn carriage sets the pace for a high-speed train today.

It's quite a yarn to suggest Gordon Moore's article from decades ago directly set the stage for tracking genome costs like it was some grand plan.
Really, it’s more like saying my neighbour buying a car in the 70s directly led to my bus pass today; you need so many other turns in the plot for that to make sense.
Without huge leaps in molecular biology and computing that Moore couldn't even dream of, his "law" would have been just a curious observation, not a blueprint for mapping human DNA.
It's a lovely story, but it forgets all the other characters and their struggles that truly made the later developments possible.

Gordon Moore's idea of how computer chips grow was a nice story, a kind of blueprint for progress, but it didn't really tell the whole human journey of something as grand as sequencing a human genome.
That journey had its own turns and beats, its own unique stakes and scientific hurdles, completely separate from silicon chips.
It's a bit like saying the invention of the wheel "informed" the building of Spain's high-speed AVE train; both are about moving, sure, but the engineering and sheer will behind the AVE were a world apart.
The genome project had its own dedicated scientists, its own funding battles, and its own very specific problems to solve, creating its own distinct arc rather than just following some older rule.

Does simply tracking the number of AI models on OpenRouter actually make those models appear or expand from 63 to 668? That's a classic marketing hype move, confusing a thermometer with the sun.
The data might show an expansion, but it doesn't prove the tracking itself caused the growth.
What really changes things for model availability is developers releasing new models, users demanding more options, or OpenRouter actively finding more providers.
Without those real drivers, a nice glossy report showing more models is just that—a report, not a mechanism that creates new ones.